CHR-2797 (tosedostat)

DRUG2 trials

Sponsors

Chroma Therapeutics

Conditions

Advanced Solid TumorsCarcinoma, Non-Small-Cell Lung

Phase 1

Clinical Trial of the Safety and Effectiveness of CHR-2797 With Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

TerminatedNCT00522938

Chroma TherapeuticsCarcinoma, Non-Small-Cell Lung

Start: 2007-12-31End: 2008-04-30Updated: 2012-06-28

Safety Study to Evaluate CHR-2797 in Patients With Advanced Tumours

CompletedNCT00692354

Chroma TherapeuticsAdvanced Solid Tumors

Start: 2004-10-31End: 2008-03-31Updated: 2010-08-06